Tilray downgraded by The Benchmark Company with a new price target
$TLRY
Medicinal Chemicals and Botanical Products
Health Care
The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | $2.25 → $2.75 | Neutral | Alliance Global Partners |
| 11/2/2022 | $3.90 | Mkt Perform | Bernstein |
| 7/29/2022 | $3.00 | Hold → Sell | The Benchmark Company |
| 3/4/2022 | $9.00 | Hold → Buy | Canaccord Genuity |
| 1/11/2022 | $7.40 → $6.90 | Neutral | Cantor Fitzgerald |
| 1/7/2022 | $11.80 → $7.40 | Neutral | Cantor Fitzgerald |
| 11/18/2021 | $10.00 | Underweight | Barclays |
| 11/1/2021 | $18.00 → $11.80 | Overweight → Neutral | Cantor Fitzgerald |
8-K - Tilray Brands, Inc. (0001731348) (Filer)
8-K - Tilray Brands, Inc. (0001731348) (Filer)
DEFA14A - Tilray Brands, Inc. (0001731348) (Filer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)